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amlodipine besylate and hydrochlorotiazide in
subjects with hypertension
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Abstract
Background: A post-hoc analysis was performed on the data from a 54 weeks phase III study (ClinicalTrials.gov identifier:
NCT00923091) to measure changes in the health-related quality of life (HRQoL) of 2,690 patients aged ≥18 with
moderate-to-severe hypertension who received one of six doses of olmesartan/amlodipine/hydrochlorothiazide (OLM/
AML/HCTZ), using the MINICHAL and EQ-5D instruments.
Methods: Descriptive statistics were used to assess blood pressure and HRQoL scores over the study period. Analysis of
covariance (ANCOVA) was used to identify those factors that could possibly have influenced HRQoL. Linear regression
was used to assess the relationship between changes in blood pressure and HRQoL scores.
Results: Patients’ baseline MINICHAL mood and somatic domains scores were 5.5 and 2.6. Over the study period HRQoL
improved as both MINICHAL scores decreased by 31-33%. Patients’ baseline EQ-5D index and VAS scores were 0.9 and
73.4 respectively, increasing by 6% and 12% over the study period. Patients’ QALY gain over the 54 weeks study period
was estimated to be 0.029 QALYs. The ANCOVA showed that changes in patients’ HRQoL was likely to have been influenced
by patients’ achievement of blood pressure control, the amount of concomitant medication and patients’ last used dosage
strength of antihypertensive. Linear regression showed that blood pressure improvement may have been associated with
improved HRQoL.
Conclusions: This study showed that OLM/AML/HCTZ reduced blood pressure and significantly increased blood pressure
control whilst improving patients’ HRQoL. Achieving blood pressure control, amount of concomitant medication and
dosage strength of antihypertensive impacted on patients’ HRQoL.
Keywords: Olmesartan, Adherence, HRQoL, Hypertension, Pill burden
Background
The risk of cardiovascular disease among hypertensive
individuals has been well documented [1], and hyperten-
sion for many is an asymptomatic disease. Recent evi-
dence suggests that hypertension may contribute to
reduce patients’ health-related quality of life (HRQoL)
when compared to that of normotensive individuals [2].
Moreover, comorbid diseases in those with arterial
hypertension can lead to a worsening of HRQoL when
compared with hypertensive patients without any comor-
bidities [2-5]. Some antihypertensive medications have
now been shown to worsen the HRQoL of hypertensive
patients [6]. However, patients receiving antihypertensive
therapy who reach their target blood pressure have an
improved HRQoL compared to untreated patients and
patients who do not reach their goal [6].
It has been estimated that 15–20% of hypertensive pa-
tients are not adequately controlled on a dual antihyperten-
sive combination and that three or more different
antihypertensive drug classes are required to achieve blood
pressure control [6-8]. The triple combination antihyper-
tensive therapy olmesartan/amlodipine/hydrochlorothiazide
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(OLM/AML/HCTZ; Sevikar HCT) has been shown to pro-
vide significantly greater blood pressure control compared
with each of the component dual combinations (i.e. OLM/
AML, OLM/HCTZ and AML/HCTZ) [9].
In a phase III, multicentred, double-blind, parallel-group
design study (ClinicalTrials.gov identifier: NCT00923091),
2,690 patients aged ≥18 years with moderate-to-severe
hypertension were randomised to receive placebo, OLM/
AML (20 mg/5 mg), OLM/AML (40 mg/5 mg) or OLM/
AML (40 mg/10 mg) for a period of 2 weeks [10]. Patients
were then allocated to one of eight groups for a further 8-
week period by being randomised to continue with the
same dose of OLM/AML, or have HCTZ (12.5 mg or
25 mg) added to their treatment.
The second stage of the study constituted an open-
label extension to assess the long-term efficacy and
safety of the triple combination. Of the 2,543 patients
who completed the double-blind phase, 2,540 patients
initially underwent 8 weeks of single-blind treatment
with OLM/AML/HCTZ (20 mg/5 mg/12.5 mg), after
which 2,509 were entered into an open-label treatment
phase. Of these, 2,439 patients (97.2%) completed the
study [11].
Patients who responded to single-blind treatment with
OLM/AML/HCTZ (20 mg/5 mg/12.5 mg) and achieved
their target blood pressure (defined as mean seated sys-
tolic blood pressure/diastolic pressure (SeSBP/DBP) <140/
90 mmHg, or <130/80 mmHg for those with diabetes or
chronic kidney or cardiovascular disease) at week 18 con-
tinued with open-label treatment of OLM/AML/HCTZ
(20 mg/5 mg/12.5 mg) for 36 weeks [11].
Patients who failed to achieve an adequate response to
OLM/AML/HCTZ (20 mg/5 mg/12.5 mg) at week 18
were entered into the first of two consecutive 4-week pe-
riods of double-blind treatment which began with re-
randomisation (1:2 ratio) to continue with OLM/AML/
HCTZ (20 mg/5 mg/12.5 mg) or up-titration to the
40 mg/5 mg/12.5 mg dose. At the end of this 4-week
period patients whose blood pressure was uncontrolled
on OLM/AML/HCTZ (20 mg/5 mg/12.5 mg) were up-
titrated to the 40 mg/5 mg/12.5 mg dose, while those
who were controlled continued with their existing treat-
ment. At week 26, all patients who had received the two
consecutive 4-week periods of double-blind treatment
entered 28 weeks of open-label treatment with OLM/
AML/HCTZ (40 mg/5 mg/25 mg). Following the start
of the open-label treatment phase, patients had their
OLM/AML/HCTZ doses titrated with an aim to achieve
blood pressure control at the investigator’s discretion
with either of the following dose combinations: 20 mg/
5 mg/12.5 mg, 40 mg/5 mg/12.5 mg, 40 mg/5 mg/
25 mg, 40 mg/10 mg/12.5 mg or 40 mg/10 mg/25 mg.
Up- and down-titration was allowed anytime based on a
patient’s response to their antihypertensive dose [11].
The 8 week double-blind phase study showed that pa-
tients in every triple OLM/AML/HCTZ group had sig-
nificantly greater mean reductions in diastolic and
systolic blood pressure compared with patients on the
corresponding OLM/AML therapy dose. During open-
label treatment with OLM/AML/HCTZ, mean SeSBP/
SeDBP levels remained within the ranges 120–140 and
75–85 mmHg, respectively. At the end of the study, sig-
nificant reductions from baseline were seen in each group
for SeSBP (37–43 mmHg) and SeDBP (22–27 mmHg),
and 78.1% of patients achieved their blood pressure goal.
At baseline, 90.8% of patients had moderate or severe
hypertension, but at the study end 91.9% had normal/high
normal blood pressure. The incidence of adverse events
was similar across all treatment groups [11].
The primary aim of this phase III study was to evalu-
ate the efficacy, safety and tolerability of the dual and
triple combination therapies, and this has been reported
elsewhere [11]. A secondary aim was to measure pa-
tients’ HRQoL over the study period. In accordance with
protocol, of the 2,690 patients who were randomised in
the double-blind study [10], 2,679 patients participated
in the HRQoL component of the study .
Methods
Health-related quality of life
A post-hoc analysis of the data collected during the phase
III trial (ClinicalTrials.gov identifier: NCT00923091) en-
abled an estimation of the HRQoL of 2,690 patients
aged ≥18 with moderate-to-severe hypertension who
received one of six doses of olmesartan/amlodipine/
hydrochlorothiazide (OLM/AML/HCTZ). Due to the
exploratory nature of the analysis, and the fact that the
statistical analysis plan was prepared after the clinical
report had been completed, the study is subject to sev-
eral limitations.
The protocol, amendments and informed consent doc-
uments were submitted to, and approved by, the Inde-
pendent Ethics Committee for each centre, prior to
study initiation. Written informed consent was received
from all patients prior to admission into the study, and
investigators ensured that the study was conducted in
accordance with the Declaration of Helsinki [10]. Patient
reported outcomes were recorded using two health-
related quality of life instruments: EQ-5D [12] and
MINICHAL [13].
The EQ-5D is a generic instrument that measures pa-
tients’ responses across 5 dimensions of health (mobility,
self-care, usual activities, pain/discomfort, and anxiety/
depression). Each dimension has 3 answers to choose
from, which can be generally classified as no problems,
moderate problems, or significant problems on the spe-
cific dimension [12]. A total of 243 possible health states
can be defined in this way, each with a unique 5 digit
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code. By applying a formula that attaches weights to
each of the levels in each dimension the 5 digit code is
converted into a single preference-based health index on
a scale from 0 (health state as bad as being dead) to 1
(full health defined by EQ-5D) [12]. The EQ-5D scores
were estimated from the preferences of a large general
population in the UK [14]. The EQ-5D also includes a
visual analog scale which is used to describe a patient’s
own health state with scores ranging from 0 (worst state)
to 100 (best state). When completing the instrument,
patients were asked to describe their own health state on
the day the questionnaire was answered [12].
The MINICHAL instrument consists of 16 items and
measures the impact of hypertension on a patient’s
HRQoL. The first 10 items are generally grouped to de-
scribe a patient’s mental state (mood domain) and the
last 6 items are designed to evaluate their somatic mani-
festations (somatic domain), i.e. the potential physical ef-
fects of hypertension. Each question has 4 response
options: 0 = No, not at all; 1 = Yes, somewhat; 2 = Yes,
quite a lot; and 3 = Yes, a great deal. The score for each
dimension is obtained by summing the scores of the
items within that dimension and scores range from 0
(best HRQoL) to 30 (worst HRQoL) for the mood do-
main and from 0 to 18 for the somatic domain [13].
For MINICHAL, patients’ completed scores were used
to calculate their mood domain, somatic domain, and
total scores according to the instrument’s specifications
and guidelines in order to evaluate changes in patients’
HRQoL during the study [13]. For the EQ-5D, patients’
scores were converted to utilities according to the in-
strument’s specifications and guidelines [12]. Patients
completed these two instruments on four occasions:
baseline, week 10, week 26 and week 54. Changes in
HRQoL from baseline to week 54 are reported as
changes in the following target variables: EQ-5D index,
EQ-5D visual analogue scale, MINICHAL mood domain,
MINICHAL somatic domain and MINICHAL total
score.
Statistical analyses
The analyses were conducted in sequential steps.
The first step involved the generation of descriptive
statistics for the following quantitative factors:
 Age at baseline (≤60 years / elderly >60 years);
 Gender;
 Weight based on BMI at baseline (normal [≤25 kg/m2],
over-weight [>25 kg/m2 to ≤30 kg/m2] and obese
[>30 kg/m2]);
 Change in systolic blood pressure in quartiles from
baseline to Week 54;
 Change in diastolic blood pressure in quartiles from
baseline to Week 54;
 Secondary prevention for cardiovascular risk factors
(diabetes, cardio-vascular disease, renal impairment);
 Smoking status (Non-Smoker/Ex-Smoker/Current
Smoker);
 Country (Eastern EU/Central-Western EU);
 Concomitant cardiovascular risk using concomitant
medications as a proxy;
 Mental disorder using concomitant medications as a
proxy;
 Number of concomitant medications per patient
during the study;
 Baseline hypertension grade (Grade 1 hypertension
SBP 140–159 mmHg or DBP 90–99 mmHg; Grade
2 hypertension SBP 160–179 mmHg or DBP
100–109 mmHg; Grade 3 hypertension
SBP ≥180 mmHg or DBP ≥110 mmHg);
 Blood pressure goal control at week 54 (SBP/
DBP ≤130/80 mmHg for diabetic patients, renally
impaired patients, or patients with cardiovascular
disease; SBP ≤140/90 mmHg for all other patients).
The second step involved performing analysis of co-
variance (ANCOVA) for each target variable and factor,
to assess if these factors possibly influenced HRQoL
changes during the study. Factors with p-value of >0.2
were omitted in the third step. Any factors with a p-
value for effect of 0.2 or lower were used in the third
step for the respective target covariate. The third step in-
volved stepwise ANCOVA that included treatment and
all pre-selected factors for each target variable based on
second step findings until all remaining factors had p-
values ≤0.05.
The outputs of the analyses were a descriptive sum-
mary of the results. P-values between 0.05 and 0.01 were
considered a trend and p-values of 0.01 or lower were
considered to be indicative. Since multiple tests were
performed without any adjustment, the p-values even if
statistically significant, should only be considered to be
indicative of trends or possible hypotheses.
Since blood pressure changes from baseline to week
54 were initially not included in the ANCOVA models, a
separate linear regression model was calculated to assess
the relationship between changes in blood pressure and
HRQoL scores from baseline.
Results
Of the 2,690 patients who were randomised into the
double-blind study [10], 2,679 patients participated in
the HRQoL component of the study. The demographic
and baseline characteristics of the 2,679 patients who
completed the HRQoL instruments at baseline are
shown in Table 1. The mean age of patients was
56.2 years; mean weight was 88.5 kg; 53.7% were female
[11]; 14.6% were diabetic; and 28.70% had cardiovascular
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disease (Table 2). The mean baseline SeSBP/SeDBP was
168.4/103.8 mmHg and 89.7% of patients had SBP be-
tween 140 and 179 mmHg or DBP between 90 and
109 mmHg (Grade 1 or 2 hypertension) whilst 10.3% had
SBP of 180 or DBP of 110 mmHg (Grade 3 hypertension)
and the mean duration of disease (hypertension) was
8.3 years.
The efficacy and safety of the alternative antihyperten-
sive combinations have been described elsewhere
[10,11]. However, it is noteworthy that differences were
observed in the baseline characteristics of patients who
ended the study in different treatment groups. For ex-
ample, the low dose OLM/AML/HCTZ 20/5/12.5 mg
group contained the lowest proportion of males, current
smokers, diabetics and patients with cardiovascular dis-
ease. In contrast, the higher dose OLM/AML/HCTZ 40/
10/12.5 and 40/10/25 mg groups contained more males
and higher proportions of diabetics and patients with
cardiovascular disease.
At baseline patients’ MINICHAL mood domain and
somatic domain scores were 5.5 and 2.6 respectively.
Over the 54 weeks study period patients’ HRQoL im-
proved as both MINICHAL scores decreased by 31-33%
(Figure 1). Patients’ baseline EQ-5D index and VAS
score was 0.9 and 73.4 respectively, (Figure 2) increasing
by 6% and 12% respectively over the study period
(Table 3). The mean difference in the EQ-5D index score
from baseline to week 54 was assessed with a univariate
procedure to calculate the change in quality-adjusted life
year (QALY). Patients’ QALY gain over the 54 weeks
study period was estimated to be 0.029 QALYs.
The majority of patients reported no problems in the
different EQ-5D dimensions, although more patients
reported experiencing pain/discomfort and anxiety/
depression than problems with the other dimensions
(Figure 3).
Results from Step 2 of the ANCOVA showed that
renal impairment and smoking status were unlikely to
have influenced the HRQoL changes observed during
the study, since their p value was >0.2. Hence, they were
omitted from the ANCOVA model in the third step.
Table 1 Patients’ characteristics
Number of patients (percentage
of sample in parentheses)
Age
<=60 years 1743 (65.1%)
>60 years 936 (34.9%)
Gender
Female 1439 (53.7%)
Male 1240 (46.3%)
Body mass index
<=25 kg/m2 309 (11.5%)
>25 to < =30 kg/m2 1003 (37.4%)
= > 30 kg/m2 1367 (51.0%)
Smoking status
Current smoker 464 (17.3%)
Ex-smoker 301 (11.2%)
Non-smoker 1914 (71.4%)
Country
Eastern European
countries
1763 (65.8%)
Western-central
European countries
916 (34.2%)
Table 2 Patients’ clinical profile
Number of patients (percentage
of sample in parentheses)
Baseline hypertension
Grade 1 27 (1.0%)
Grade 2 2375 (88.7%)
Grade 3 277 (10.3%)
Diabetes
No 2287 (85.4%)
Yes 392 (14.6%)
Cardiovascular
disease
No 1911 (71.3%)
Yes 768 (28.7%)
Renal impairment
No 2625 (97.9%)
Yes 54 (2.0%)
Cardiovascular
risk
Yes 566 (21.1%)
No 2113 (78.9%)
Mental Disorder
Yes 153 (5.7%)
No 2526 (94.3%)
Concomitant
medications
0 417 (15.6%)
1-2 857 (32.0%)
3-4 635 (23.7%)
5-6 371 (13.9%)
= > 7 399 (14.9%)
Achieved hypertension
goal by week 54
Missing data 171 (6.4%)
No 549 (20.5%)
Yes 1959 (73.1%)
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Blood pressure changes in quartiles were also excluded
from the third step as that was pre-determined by the
analysis protocol. The factors/endpoints with a p value
of <0.05 after performing Step 3 of the ANCOVA are
summarised in Tables 4 and 5. Whilst these p values are
explorative only, they are indicative of those baseline fac-
tors that influenced the patients’ HRQoL status at the
end of the study period. Nevertheless, there were very
slight differences in the change in patients’ HRQoL over
the study period when stratified by the different baseline
factors. For example, the change in HRQoL was similar
irrespective of patients’ age, gender, BMI, etc. The one
exception to this was in patients’ baseline hypertension
grade. The change in HRQoL for patients with Grade 2
and 3 hypertension was similar, but different to that of
patients with Grade 1 when assessed using the EQ-5D
VAS. However, patients’ baseline hypertension grade was
found not to have influenced HRQoL when assessed
using the MINICHAL. Similarly, neither the presence of
cardiovascular disease nor patients’ use of concomitant
medication for cardiovascular disease or mental disorder
appeared to influence their HRQoL when assessed by
MINICHAL. Conversely, the amount of concomitant
medication (“pill burden”), blood pressure target
achievement and patients’ antihypertensive treatment in
period 6 influenced HRQoL when assessed by the EQ-
5D but not when assessed by the MINICHAL. Notwith-
standing this, patients’ baseline HRQoL score derived
from each scale influenced their HRQoL score on that
same scale at week 54.
The factors included in the EQ-5D VAS step 3 model
are not exhaustive and do not account for all of the ob-
served difference in VAS score. The R2 for the
ANCOVA model was 0.188. The different factors incor-
porated in the separate EQ-5D index, MINICHAL mood
and MINICHAL somatic step 3 models are likely to be
more influential over the changes in patients’ HRQoL
and the R2 was 0.408, 0.431 and 0.448 respectively. Not-
withstanding this, changes in the patients’ HRQoL was
possibly influenced by other factors which were not
measured in this study. Additionally, a separate linear
regression analysis showed that blood pressure improve-
ment may have been associated with improved HRQoL.
Discussion
This study assessed the HRQoL of hypertensive patients
who received one of six doses of OLM/AML/HCTZ to
reduce their high blood pressure using both the EQ-5D
and MINICHAL instruments over 54 weeks including
the open label phase. At the start of the study, 90.8% of
patients had Grade 2 or 3 hypertension, but at the study
end 91.9% had achieved the SeSBP <140 mmHg thresh-
old [11]. Furthermore, the incidence of adverse events
was similar across the treatment groups [11]. Patients’
hypertension grade at baseline did not appear to affect
their HRQoL, except the EQ-5D VAS score of those
with Grade 3 disease was lower than that of the other
patients. This may reflect the admission criteria of the
clinical trial [10,11] since patients’ baseline health status
was relatively high. In contrast, others have reported that
patients with Grade 1 disease have better MINICHAL
scores than those with Grade 2/3 [15,16].
Previous studies using the MINICHAL have shown
that patients treated with antihypertensives who experi-
enced reduced blood pressure experienced a greater de-
crease in MINICHAL scores than those patients who
reported no overall change in blood pressure. In this
study, patients’ HRQoL improved since their MINICHAL
scores decreased by 31-33% over the 54 weeks study
period. However, what constitutes clinically relevant
changes in MINICHAL scores is currently undecided. The
mean mood and somatic MINICHAL scores among a
normotensive population in Brazil have been estimated at
3.2 and 0.8 respectively [17]. The corresponding values
0.0
1.0
2.0
3.0
4.0
5.0
6.0
1 8 15 22 29 36 43 50 57
Mean MINICHAL 
score per patient
Time from the start of treatment (weeks)
MINICHAL mood domain
MINICHAL somatic domain
Figure 1 Mean MINICHAL scores per patient at different times from the start of antihypertensive treatment. Not all patients completed
all HRQoL instruments at each time point.
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among the hypertensive population in the Brazilian study
was 5.3 and 1.9 respectively [17]. Other studies that have
used the MINICHAL reported mean mood scores of 6.6
[18] and 5.6 [15] and mean somatic scores of 5.0 [18] and
2.1 [15]. In the present study the mean mood and somatic
baseline scores of 5.5 and 2.6 respectively were concordant
with those from the other studies [15,17,18]. Notwith-
standing the variance between studies, use of the MINI-
CHAL detected that the patients in the present study had
a poorer HRQoL than would be expected from normoten-
sive patients, which is consistent with the finding of others
[19]. Moreover, the somatic domain appeared to be more
sensitive than the mood domain in the detecting changes
in patients’ HRQoL in this study.
The ANCOVA model showed that multiple factors in-
fluenced HRQoL changes. However, individual categor-
ical variables (as identified in step 3) would seem to have
only accounted for up to 40% of the variation in patients’
HRQoL (measured using the MINICHAL), since R2 was
of the order of 0.4. This value indicates that other vari-
ables (such as socioeconomic factors and stress which
were not measured in the clinical trials) have not been in-
cluded in the ANCOVA model and thus it was not pos-
sible to control for their effect. Nevertheless, achievement
of blood pressure target was found to be an influencer for
HRQoL. Both these variables have been shown to be inde-
pendent predictors of HRQoL among hypertensive pa-
tients [20,21]. Also, step 3 of the MINICHAL model
suggests that the amount of co-medication (“pill burden”)
affects patients’ HRQoL. Moreover, a high pill burden
among hypertensive patients has been shown to adversely
affect adherence [22,23]. Therefore, the findings from this
study support the notion that physicians should pre-
scribe in a manner to reduce their patients’ pill burden.
Additionally, the HRQoL of patients treated with an
anti-hypertensive in an observational study was found
to significantly influence adherence to treatment [24]. Fur-
thermore, patients with high adherence to their treatment
schedule have a much higher chance of attaining their tar-
get blood pressure than patients with low adherence [25].
Consequently, adherence plays an important role in redu-
cing the risk of developing cardiovascular events [26].
Moreover, achieving blood pressure control influenced pa-
tients’ HRQoL, as demonstrated by the step 3 EQ-5D
index and MINICHAL somatic domain models, despite
patients’ high baseline health status.
The mean EQ-5D index and VAS baseline scores for
the whole study cohort was 0.9 and 73.4 respectively.
0
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Mean EQ5D VAS 
score per patient
Mean EQ5D index 
score per patient
Time from the start of treatment (weeks)
EQ5D Index EQ5D VAS
Figure 2 Mean EQ-5D scores per patient at different times from the start of antihypertensive treatment. Not all patients completed all
HRQoL instruments at each time point.
Table 3 Patients’ mean (standard deviation) blood pressure and health-related quality of life status*
Baseline Week 54 Difference between week
54 and baseline
p value derived
using a t-test
Systolic blood pressure 168.4 (6.6) 127.1 (9.0) −41.3 (10.0) <0.0001
Diastolic blood pressure 103.8 (2.9) 78.0 (6.6) −25.9 (6.9) <0.0001
EQ-5D index 0.90 (0.13) 0.95 (0.11) 0.05 (0.12) <0.0001
EQ-5D VAS 73.4 (15.0) 82.3 (12.5) 8.9 (14.4) <0.0001
MINICHAL mood domain 5.45 (4.42) 3.68 (3.74) −1.80 (4.24) <0.0001
MINICHAL somatic domain 2.62 (2.66) 1.80 (2.16) −0.80 (2.46) <0.0001
MINICHAL total score 8.00 (6.22) 5.40 (5.12) −2.60 (5.68) <0.0001
*Not all patients completed all HRQoL instruments at each time point.
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These baseline scores are high, probably due to the fact
that patients with major concomitant cardiovascular risk
factors and co-morbidities were excluded by the clinical
trial protocol. Nonetheless, these scores increased by 6%
and 12% respectively over the study period. In compari-
son, the international population norm for the EQ-5D
index across the 18 to 75+ age group has been reported
to range from 0.74 to 0.95 and that of the EQ-5D VAS
has been shown to range from 71.1 to 83.7 [27]. These
comparisons suggest that the EQ-5D index score of this
patient population is higher relative to population norms
than the EQ-5D VAS, which may suggest that the EQ-
5D index is not a sufficiently sensitive instrument with
which to measure HRQoL among hypertensive patients
with no major additional cardiovascular risk factors.
Notwithstanding this, the analysis showed that age, gen-
der, BMI, whether patients were taking cconcomitant medi-
cation for cardiovascular disease and/or mental disorder
and whether they achieved hypertension control by week
54 all influenced the EQ-5D index score. Additionally, gen-
der, co-morbid diabetes, co-morbid cardiovascular disease,
country of origin, whether patients were taking concomi-
tant medication for mental disorder and their hypertension
grade at baseline influenced their EQ-5D VAS score. The
effect of concomitant cardiovascular diseases on HRQoL
has been much debated in the published literature. For ex-
ample, the epidemiological study ESTHER showed that in a
large cohort of hypertensive patients being managed by
general practitioners, additional cardiovascular risk factors
did not seem to be related to a substantial worsening of
their HRQoL measured using the SF-12. Nonetheless, the
physical component score (PCS) reported in the ESTHER
study was found to be significantly decreased by cardiovas-
cular risk factors such as BMI, macroalbuminuria, diabetes
and circulatory disorders [28]. In our phase III study
study on OLM/AML/HCTZ the analysis of patients’ co-
morbidities suggested that the study population com-
prised a relatively healthy cohort with relatively few
experiencing comorbid illness, reflecting the exclusion
criteria of the trial. The possibility of a “ceiling effect” in
EQ-5D index because of the high baseline values (37.3%
of patients had an EQ-5D value of 1.00) leading to
artifactual parameter estimates in the ANCOVA cannot
be excluded. It was not considered appropriate to reduce
the potential impact of a ceiling effect as available econo-
metric methods [29] have been applied to simple ordinary
least squares regression models, but not to ANCOVA
models that incorporate covariates. Notwithstanding the
limitations of using the EQ-5D instrument to detect
HRQoL changes among hypertensive patients, it did de-
tect important differences in those who had controlled
their hypotension.
The Step 3 analyses identified multiple factors that
were likely to have influenced HRQoL simultaneously.
Blood pressure control was the only blood pressure-
related factor modelled in Step 3. However, linear re-
gression showed that blood pressure improvement may
have been associated with improved HRQoL.
This post-hoc analysis is subject to several other limi-
tations. The statistical analysis protocol for the post-hoc
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60%
70%
80%
90%
100%
Baseline Week 54 Baseline Week 54 Baseline Week 54 Baseline Week 54 Baseline Week 54
No problem Moderate problem Extreme problemPercent of patients
Pain/discomfort Anxiety/depression Selfcare Mobility Usual activities
Figure 3 Percentages of patients reporting problems across each EQ-5D index dimension at baseline and after 54 weeks of treatment.
Data was missing from 10% of patients at baseline and 1% of patients at week 54.
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Table 4 Results of Step 3 from the ANCOVA investigating the relationship between sociodemographic factors and morbidity on patients’ health-related quality
of life measured using the EQ-5D
Endpoint/Factors EQ-5D Index EQ-5D VAS
Baseline Difference between
week 54 and baseline
p value Baseline Difference between
week 54 and baseline
p value
Age class <0.0001
<=60 years 0.92 (0.12) 0.00 (0.12)
>60 years 0.89 (0.14) 0.00 (0.13)
Gender 0.0005 0.0002
Male 0.94 (0.11) 0.00 (0.10) 75.6 (14.2) −8.50 (13.59)
Female 0.89 (0.15) 0.00 (0.14) 71.4 (15.4) −9.30 (15.08)
BMI 0.0426
<=25 kg/m2 0.94 (0.11) 0.00 (0.12)
>25 to < =30 kg/m2 0.92 (0.13) 0.00 (0.12)
= > 30 kg/m2 0.91 (0.13) 0.00 (0.13)
Diabetes 0.0101
Yes 69.2 (15.4) −8.60 (15.91)
No 74.1 (14.8) −8.90 (14.14)
Cardiovascular disease <0.0001
Yes 70.4 (14.5) −10.90 (13.83)
No 74.5 (15.5) −8.10 (14.55)
Country (region) 0.0085
Western-central countries 76.0 (15.5) −7.80 (15.50)
Eastern countries 72.0 (14.5) −9.40 (13.81)
Concomitant medication for
cardiovascular disease
0.0065
Yes 0.91 (0.13) 0.00 (0.12)
No 0.92 (0.12) 0.00 (0.13)
Concomitant medication for
mental disorder
0.021 0.0263
Yes 0.88 (0.17) 0.00 (0.19) 68.7 (17.8) −10.40 (18.05)
No 0.92 (0.13) 0.00 (0.12) 73.6 (14.7) −8.80 (14.22)
Hypertension grade at
baseline
0.0258
Grade 1 80.6 (11.8) −1.10 (11.09)
Grade 2 73.4 (15.0) −8.80 (14.25)
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Table 4 Results of Step 3 from the ANCOVA investigating the relationship between sociodemographic factors and morbidity on patients’ health-related quality
of life measured using the EQ-5D (Continued)
Grade 3 72.4 (15.2) −10.40 (15.67)
Achieved hypertension
control by week 54
0.0019
Yes 0.92 (0.13) 0.00 (0.12)
No 0.89 (0.15) 0.00 (0.14)
Baseline value of respective
endpoint
<0.0001 <0.0001
SeSBP changes from baseline
to week 54
0.0010 0.0160
SeDPB changes from baseline
to week 54
0.0039 0.0120
*The baseline values (standard deviation) and differences (standard deviation) between week 54 and baseline were calculated independently of the Step 3 model.
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Table 5 Results of Step 3 from the ANCOVA investigating the relationship between sociodemographic factors and morbidity on patients’ health-related quality
of life measured using the MINICHAL*
Endpoint/Factors MINICHAL mood domain MINICHAL somatic domain MINICHAL total score
Baseline Difference between
week 54 and baseline p value
Baseline Difference between
week 54 and baseline p value
Baseline Difference between
week 54 and baseline
p value
Age class <0.0001 0.0058 <0.0001
<=60 years
5.34 (4.38)
−2.00 (4.21) 2.51 (2.68) −0.80 (2.46) 7.80 (6.24) −2.80 (5.67)
>60 years 5.63 (4.48) −1.40 (4.27) 2.81 (2.61) −0.70 (2.45) 8.38 (6.16) −2.00 (5.66)
Gender 0.0151 0.0004 0.0045
Male 4.74 (4.10) −1.60 (4.00) 2.18 (2.34) −0.70 (2.22) 6.88 (5.66) −2.30 (5.38)
Female 6.06 (4.59) −1.90 (4.43) 2.99 (2.86) −0.90 (2.64) 8.99 (6.51) −2.80 (5.92)
BMI 0.0063
<=25 kg/m2 2.32 (2.50) −0.80 (2.03)
>25 to < =30 kg/m2 2.33 (2.53) −0.80 (2.40)
= > 30 kg/m2 2.89 (2.76) −0.80 (2.58)
Diabetes 0.0326
Yes 5.80 (4.70) −1.40 (4.52)
No 5.38 (4.37) −1.90 (4.19)
Country (region) <0.0001 <0.0001
Western-central
countries
4.56 (4.66) −1.80 (4.42) 6.70 (6.45) −2.30 (5.97)
Eastern countries 5.90 (4.22) −1.80 (4.14) 8.68 (5.98) −2.70 (5.52)
Amount of concomitant
medication
0.0387 <0.0001 0.0002
0 5.79 (4.27) −2.20 (4.30) 2.43 (2.42) −1.00 (2.05) 8.21 (5.77) −3.20 (5.24)
1-2 5.44 (4.32) −1.90 (3.92) 2.32 (2.55) −0.80 (2.38) 7.69 (6.00) −2.70 (5.25)
3-4 5.15 (4.22) −1.80 (4.02) 2.73 (2.78) −0.80 (2.53) 6.00 (5.06) −2.50 (5.70)
5-6 5.38 (4.37) −1.30 (4.40) 2.91 (2.78) −0.70 (2.55) 8.28 (6.22) −2.00 (5.97)
= > 7 5.61 (5.08) −1.50 (5.01) 3.01 (2.75) −0.60 (2.85) 8.57 (7.00) −2.00 (6.77)
Achieved hypertension
control by week 54
0.002 0.011
Yes 2.44 (2.59) −0.80 (2.37) 7.75 (6.13) −2.70 (5.62)
No 3.13 (2.85) −0.70 (2.77) 8.67 (6.33) −2.20 (5.90)
Treatment in Period 6 0.0158 0.0012 0.024
OM20/AML5/HCTZ12.5 5.19 (4.24) −1.90 (4.23) 2.39 (2.59) −0.80 (2.32) 7.48 (5.99) −2.60 (5.59)
OM40/AML5/HCTZ12.5 5.94 (5.05) −1.40 (4.80) 3.02 (3.04) −1.00 (3.02) 8.93 (7.09) −2.40 (6.81)
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Table 5 Results of Step 3 from the ANCOVA investigating the relationship between sociodemographic factors and morbidity on patients’ health-related quality
of life measured using the MINICHAL* (Continued)
OM40/AML5/HCTZ25 5.94 (4.58) −2.00 (4.12) 2.67 (2.58) −0.90 (2.49) 8.59 (6.22) −2.90 (5.50)
OM40/AML10/HCTZ12.5 5.69 (4.39) −1.70 (3.90) 3.19 (2.95) −0.50 (2.77) 8.95 (6.46) −2.30 (5.88)
OM40/AML10/HCTZ25 4.83 (3.89) −1.20 (3.88) 2.86 (2.43) −0.50 (2.25) 7.67 (5.41) −2.00 (4.73)
Baseline value of
respective endpoint
<0.0001 <0.0001 <0.0001
SeSBP changes from
baseline to week 54
0.0089 0.0002 0.0006
SeDPB changes from
baseline
to week 54
0.1089 0.0080 0.0273
*The baseline values (standard deviation) and differences (standard deviation) between week 54 and baseline were calculated independently of the Step 3 model.
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HRQoL analysis was prepared after the clinical report
had been completed. Multiple statistical tests were per-
formed without any adjustment. Hence, the p-values can
only be viewed as being exploratory and indicative of
trends or possible hypotheses. Furthermore, the large
sample size may have resulted in small, statistically sig-
nificant p values for changes that may have marginal
clinical significance. Factors that may have influenced
patients’ HRQoL, such as educational level, marital sta-
tus, job status, income and residency, were not collected
during the phase III trial. Exclusion of these factors
should be considered as an additional limitation. More-
over, the large sample size of this non-comparative study
has only generated small effects. Hence, the reproduci-
bility of the HRQoL impact of OLM/AML/HCTZ seen
in this study needs to be studied further in a controlled
study design.
In conclusion, this present study showed that OLM/
AML/HCTZ reduced blood pressure and significantly in-
creased blood pressure control whilst improving patients’
HRQoL. Achieving blood pressure control, amount of
concomitant medication and dosage strength of antihyper-
tensive all impacted on patients’ HRQoL. Hence, when
prescribing antihypertensive agents physicians should con-
sider the impact of all these factors on patients’ HRQoL
and on their adherence to treatment.
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